VasoDrive-AP
Also known as: AmealPeptide, valine-prolyl-proline (VPP), isoleucine-prolyl-proline (IPP), lactotripeptides, VasoDrive-AP
Overview
VasoDrive-AP is a patented peptide complex consisting primarily of two lactotripeptides: valine-prolyl-proline (VPP) and isoleucine-prolyl-proline (IPP). These bioactive peptides are derived from the enzymatic hydrolysis of milk casein proteins. It is primarily used as a cardiovascular health supplement to improve arterial flexibility, reduce blood pressure, and enhance endothelial function. VasoDrive-AP functions by inhibiting angiotensin-converting enzyme (ACE), leading to vasodilation and improved blood flow. It is recognized as safe by the FDA (GRAS) and is FOSHU-certified in Japan, with its efficacy supported by over 30 published studies, including numerous double-blind, placebo-controlled human clinical trials. While present in milk, therapeutic effects require supplementation due to insufficient quantities in regular dairy consumption.
Benefits
VasoDrive-AP offers significant cardiovascular benefits, primarily through its blood pressure-lowering effects. A meta-analysis of 30 randomized controlled trials (RCTs) on lactotripeptides, including VPP and IPP, reported clinically meaningful reductions in systolic blood pressure (SBP) and diastolic blood pressure (DBP), typically in the range of 3–5 mm Hg for SBP. These reductions are considered clinically relevant for cardiovascular risk reduction. Multiple RCTs have also demonstrated improvements in arterial elasticity and endothelial function, with effects observed within 3-4 weeks of daily supplementation. Secondary benefits include enhanced exercise performance and recovery, attributed to improved blood flow and endothelial nitric oxide synthase (eNOS) activity. Some research suggests a modest increase (approximately 5%) in maximal muscle power. VasoDrive-AP is particularly beneficial for individuals with prehypertension or mild hypertension, with positive but less pronounced effects in healthy populations. The evidence supporting these benefits is robust, including systematic reviews and meta-analyses.
How it works
VasoDrive-AP primarily exerts its effects by inhibiting angiotensin-converting enzyme (ACE). ACE is responsible for converting angiotensin I to angiotensin II, a potent vasoconstrictor. By inhibiting ACE, VasoDrive-AP reduces the production of angiotensin II, leading to vasodilation and a subsequent reduction in blood pressure. This mechanism directly impacts the renin-angiotensin system (RAS), improving overall vascular tone. Additionally, VasoDrive-AP stimulates endothelial nitric oxide synthase (eNOS), which increases the production of nitric oxide (NO). NO is a crucial signaling molecule that promotes vasodilation, further contributing to improved blood flow and endothelial function. The lactotripeptides are low molecular weight and bioavailable, allowing them to be absorbed and exert their systemic effects.
Side effects
VasoDrive-AP is generally recognized as safe (GRAS) and has shown an excellent safety profile in clinical trials, with no significant adverse effects reported. There are no common (greater than 5%), uncommon (1-5%), or rare (less than 1%) side effects documented in the available research. Regarding drug interactions, no significant interactions have been documented. However, caution is advised if VasoDrive-AP is combined with other ACE inhibitors or antihypertensive medications, as this could potentially lead to an additive effect on blood pressure. Contraindications are not firmly established, but individuals with known allergies to milk proteins should avoid VasoDrive-AP due to its milk-derived origin. It is considered safe for general adult populations, but data on its use in pregnant or lactating women are limited, and caution is recommended in these groups.
Dosage
The minimum effective dose of VasoDrive-AP for blood pressure reduction has been demonstrated at approximately 150 mg per day. Optimal dosage ranges typically fall between 150 mg and 508 mg per day. Higher doses, such as 508 mg, have been used in licensed applications like AmealPeptide and consistently show benefits. There are no reported adverse effects at studied doses, and while an upper limit for safety has not been clearly defined, it is considered safe within these tested ranges. For optimal results, daily supplementation with consistent intake is recommended. The beneficial effects, including improvements in blood pressure and vascular function, typically manifest after 3-4 weeks of continuous use. VasoDrive-AP is available in various forms, including dietary supplements and functional beverages. The peptides are efficiently absorbed, and their bioavailability is supported by positive clinical outcomes. No specific cofactors are required for its efficacy.
FAQs
Is VasoDrive-AP safe for long-term use?
Clinical trials up to several weeks have shown VasoDrive-AP to be safe and well-tolerated. While long-term data are limited, no safety concerns have emerged from current research.
How quickly does VasoDrive-AP work?
Improvements in blood pressure and vascular function typically become noticeable within 3-4 weeks of consistent daily supplementation.
Can VasoDrive-AP replace prescription blood pressure medications?
VasoDrive-AP can support blood pressure management, but it should not replace prescribed antihypertensive medications without direct medical supervision from a healthcare professional.
Is VasoDrive-AP effective at low doses?
Yes, VasoDrive-AP has demonstrated efficacy at doses as low as 150 mg per day, which is notably lower than the gram-level doses often required for other vasodilators like L-citrulline.
Does VasoDrive-AP cause any muscle pump or performance enhancement?
Some evidence suggests a modest improvement in maximal muscle power (around 5%), likely due to enhanced blood flow. However, its primary established use is for cardiovascular health.
Research Sources
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4303860/ – This meta-analysis of 30 randomized controlled trials (RCTs) on lactotripeptides, including VPP and IPP, found significant reductions in both systolic and diastolic blood pressure. The study confirmed a consistent ACE inhibition effect, supporting the use of lactotripeptides for blood pressure management, though it noted some reporting quality issues in individual studies.
- https://www.cambridge.org/core/services/aop-cambridge-core/content/view/0912BFD06F43D07284799A08C8094E73/S0007114521003676a.pdf/div-class-title-role-of-whey-protein-in-vascular-function-a-systematic-review-and-meta-analysis-of-human-intervention-studies-div.pdf – This systematic review and meta-analysis investigated the role of whey protein, a source of lactotripeptides, in vascular function. It concluded that whey protein supplementation improves endothelial function, arterial stiffness, and nitric oxide production, providing further support for the vascular benefits of these bioactive peptides.
- https://blog.priceplow.com/supplement-news/core-nutritionals-pump/fun-sweets-cotton-candy-vasodrive-ap – This review, referencing various clinical trials, highlights VasoDrive-AP's ability to reduce blood pressure at low doses (150 mg/day). It suggests VasoDrive-AP's efficacy is superior to higher doses of L-citrulline for blood pressure reduction, cross-referencing manufacturer data with independent RCTs.
- https://www.maypro.com/products/vasodrive-ap – This source provides an overview of VasoDrive-AP, emphasizing its role in improving arterial flexibility and endothelial function. It highlights the ingredient's mechanism of action as an ACE inhibitor and its support by clinical research, noting effects observed within 3-4 weeks of supplementation.
- https://blog.priceplow.com/supplement-news/granite-supplements-vaso-blast – This article discusses VasoDrive-AP's benefits, referencing a peer-reviewed study from the Nutrients journal. It supports the claim that VasoDrive-AP supplementation reduces blood pressure and improves endothelial function, aligning with broader meta-analytic findings on lactotripeptides.
- https://nutrabio.com/blogs/blog/unbent-the-pump-so-good-your-arms-wont-bend – This article discusses the potential for VasoDrive-AP to enhance exercise performance and recovery through improved blood flow and eNOS activity. It also touches upon the modest increase in maximal muscle power linked to its vascular effects.
